| HOME >> BIOLOGY >> TECHNOLOGY |
IRVING, Texas, March 8, 2013 /PRNewswire/ -- Caris Life Sciences™, a leading biosciences company focused on fulfilling the promise of personalized medicine, will sponsor an expert symposium, Integrating Next Generation Sequencing Into the Clinical Management of Gynecologic Cancers, at the 2013 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer® in Los Angeles, Calif.
The symposium, which will take place Sunday, March 10, at 1 p.m. PDT, is designed to update the gynecologic oncology community on technological and clinical advances that may impact and shape the management and therapy optimization for gynecologic cancers both today and in the near future. The program will feature presentations by several prominent experts in the application of tumor profiling in gynecologic oncology.
The expert panel will also discuss the clinical importance of utilizing a multi-platform approach, such as that provided by Molecular Intelligence™ Services, when profiling gynecological malignancies. Molecular Intelligence from Caris Life Sciences is the world's foremost evidence‐based tumor profiling service, providing oncologists with relevant, clinically actionable and individualized treatment information to personalize therapy regimens for their cancer patients.
"Recent technological advances, including the introduction of next generation sequencing (NGS), have expanded the ability to more rapidly and broadly profile gynecological malignancies," said symposium course director Robert Coleman , M.D., professor of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas. "This symposium will provide a glimpse into how this emerging tool has enabled significantly improved access to genetic information from cancer patients, many times revealing critical in
'/>"/>
| SOURCE Caris Life Sciences Copyright©2012 PR Newswire. All rights reserved |